Biopharmaceutical Company Alimera Sciences Inc. said the Austrian health regulator approved its experimental drug Iluvien for retinal swelling, raising hopes for the company's most advanced treatment, which has been twice rejected in the United States.The drug was approved for chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Iluvien is a sustained release intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months.Seven European countries -- United Kingdom, Austria, France, Germany, Italy, Portugal and Spain -- had found Iluvien to be "approvable" in a "Final Assessment Report" in late February.To see more details visit, www.medscape.com
